Alluvi, formerly LY3414901, represents a significant advancement in weight management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist demonstrates remarkable efficacy in early clinical data, with substantial slimming observed